The European Commission (EC) has granted marketing authorization to Bristol Myers Squibb’s (BMS) chimeric antigen receptor (CAR) T-cell immunotherapy, Breyanzi (lisocabtagene maraleucel; liso-cel), to treat relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) in adult patients.

With a specified composition and 4-1BB costimulatory domain, Breyanzi is a cluster of differentiation 19 (CD19)-directed CAR T-cell immunotherapy. 

As per the latest authorisation, the cell therapy is also indicated to treat primary mediastinal large B-cell lymphoma (PMBCL) and follicular lymphoma grade 3B (FL3B) following treatment with two or more lines of systemic therapy. 

Breyanzi is administered as a tailored treatment through a single infusion. 

It showed continued complete responses in an increased number of R/R LBCL patients with a manageable and distinguished safety profile, BMS noted.

The latest development is based on findings from the multicentre, open-label Phase I TRANSCEND NHL 001 study of Breyanzi in adult individuals with R/R DLBCL, PMBCL and FL3B. 

Carried out in the US, the trial analysed the safety, antitumor activity and pharmacokinetics of Breyanzi.

According to the trial findings from 216 subjects who received Breyanzi and were evaluable for efficacy, 73% of them attained achieved a response.

Furthermore, 53% of them had minimal or no detectable lymphoma after receiving the treatment.

The safety of Breyanzi was established based on pooled data from four studies, TRANSCEND NHL 001, TRANSCEND WORLD, PLATFORM and OUTREACH, in R/R LBCL patients.

Neutropenia, anaemia, leukopenia, thrombocytopenia, infection and febrile neutropenia were the most common Grade >3 adverse reactions linked to Breyanzi treatment. 

Bristol Myers Squibb chief medical officer Samit Hirawat said: “Breyanzi addresses an ongoing unmet need for patients in Europe battling relapsed or refractory large B-cell lymphoma who have few treatment options that provide long-term remission. 

“The EC approval of Breyanzi is a significant step towards bringing the novel and personalised science of CAR T cell therapies to more patients around the world.”

In February this year, the US Food and Drug Administration granted priority review to Bristol Myers Squibb’s supplemental Biologics License Application (sBLA) for Breyanzi to treat adults with R/R LBCL.

Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.

Free Whitepaper

Secure the cell therapy supply chain from bench to bedside

The development of cell therapies is changing healthcare, delivering new hope to thousands of patients around the world. The vein-to-vein workflow for these therapies, however, is not without challenges, many of which will increase as we scale up to treat more patients. Download this free guide from Cytiva to learn more about the challenges and risks associated with the cryogenic supply chain for cell therapies, and how supply chain disruptions can best be mitigated.

by Cytiva Thematic

By clicking the Download Free Whitepaper button, you accept the terms and conditions and acknowledge that your data will be used as described in the Cytiva Thematic privacy policy

By downloading this Whitepaper, you acknowledge that we may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Visit our privacy policy for more information about our services, how we may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.